Chronic Rejection After Kidney Transplantation

• Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

  2021 The Lancet Neurology article Medicine Myasthenia Gravis and Thymoma Open access cited by 7 patents

  733

  citations
• The Banff 2022 Kidney Meeting Report: Reappraisal of microvascular inflammation and the role of biopsy-based transcript diagnostics

  2023 American Journal of Transplantation article Medicine Renal Transplantation Outcomes and Treatments Open access

  293

  citations
• Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design

  2022 Trials article Medicine Renal Transplantation Outcomes and Treatments Open access

  45

  citations
• Multiomic profiling of transplant glomerulopathy reveals a novel T-cell dominant subclass

  2023 Kidney International article Medicine Renal Transplantation Outcomes and Treatments Open access

  34

  citations
• Human leukocyte antigen class I antibody-activated endothelium promotes CD206+ M2 macrophage polarization and MMP9 secretion through TLR4 signaling and P-selectin in a model of antibody-mediated rejection and allograft vasculopathy

  2023 American Journal of Transplantation article Medicine Transplantation: Methods and Outcomes Open access

  17

  citations
• Banff 2022 Kidney Commentary: Reflections and Future Directions

  2024 Transplantation editorial Medicine Renal Transplantation Outcomes and Treatments Open access

  7

  citations

6 results